# Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

> **NCT03382600** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Oxaliplatin
- **DRUG:** TS-1
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03382600
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382600, "Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT03382600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*